Literature DB >> 23411106

Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial).

Tullio Palmerini1, Philippe Généreux, Roxana Mehran, George Dangas, Adriano Caixeta, Diego Della Riva, Andrea Mariani, Ke Xu, Gregg W Stone.   

Abstract

Although inflammation is involved in the pathogenesis of acute coronary syndromes, the extent of inflammation is not routinely assessed, and its prognostic implications in patients with non-ST-segment elevation acute coronary syndrome have not been investigated in depth. We analyzed the prognostic implications of an elevated white blood cell count (WBCc) in patients with moderate and high-risk non-ST-segment elevation acute coronary syndrome undergoing an early invasive strategy in the large-scale Acute Catheterization and Urgent Intervention Triage StrategY trial. The WBCc at admission was available for 13,678 of 13,819 patients (98.9%). The patients in the upper tertile of the WBCc had an increased risk of 30-day major bleeding, 1-year mortality, and definite/probable stent thrombosis compared to those in the mid or lower tertiles. On multivariate analysis, the WBCc was an independent predictor of 30-day major bleeding and 1-year cardiac, noncardiac, and all-cause mortality. The association between the WBCc and cardiac mortality was present in multiple prespecified subgroups, with no significant interaction between the WBCc and age, gender, diabetes, smoking, renal dysfunction, elevated baseline biomarkers, antithrombotic therapy, revascularization, and Thrombolysis In Myocardial Infarction risk score. The WBCc remained an independent predictor of mortality after adjusting for bleeding, C-reactive protein level, and angiographic variables, including left ventricular ejection fraction, Thrombolysis In Myocardial Infarction flow, and number of diseased vessels. The WBCc significantly improved the prognostic accuracy of the Thrombolysis In Myocardial Infarction risk score, with a net reclassification improvement of 11% (p <0.0001). In conclusion, in patients with moderate- and high-risk non-ST-segment elevation acute coronary syndrome, an elevated admission WBCc was an independent predictor of 30-day major bleeding, and 1-year cardiac, noncardiac, and all-cause mortality.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411106     DOI: 10.1016/j.amjcard.2012.12.056

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Elevated mean neutrophil volume represents altered neutrophil composition and reflects damage after myocardial infarction.

Authors:  G P J van Hout; W W van Solinge; C M Gijsberts; M P J Teuben; P H C Leliefeld; M Heeres; F Nijhoff; S de Jong; L Bosch; S C A de Jager; A Huisman; P R Stella; G Pasterkamp; L J Koenderman; I E Hoefer
Journal:  Basic Res Cardiol       Date:  2015-10-14       Impact factor: 17.165

2.  Association between body mass index and the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran: a cohort study.

Authors:  Ming-Hui Li; Li-Hua Hu; Yu-Rong Xiong; Yu Yu; Wei Zhou; Tao Wang; Ling-Juan Zhu; Xi Liu; Hui-Hui Bao; Xiao-Shu Cheng
Journal:  J Geriatr Cardiol       Date:  2020-04       Impact factor: 3.327

3.  Relation of leukocytes and its subsets counts with the severity of stable coronary artery disease in patients with diabetic mellitus.

Authors:  Li-Feng Hong; Xiao-Lin Li; Song-Hui Luo; Yuan-Lin Guo; Jun Liu; Cheng-Gang Zhu; Ping Qing; Rui-Xia Xu; Na-Qiong Wu; Li-Xin Jiang; Jian-Jun Li
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

4.  Correlation between leukocyte count and infarct size in ST segment elevation myocardial infarction.

Authors:  Júlia Peixoto Ferrari; Maria Emília Lueneberg; Roberto Leo da Silva; Tammuz Fattah; Carlos Antônio Mascia Gottschall; Daniel Medeiros Moreira
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-06-21

5.  Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.

Authors:  Jessica Ristorto; Nathan Messas; Benjamin Marchandot; Marion Kibler; Sébastien Hess; Nicolas Meyer; Michael Schaeffer; Nicolas Tuzin; Patrick Ohlmann; Laurence Jesel; Olivier Morel
Journal:  J Atheroscler Thromb       Date:  2018-02-08       Impact factor: 4.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.